GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Inc (ROCO:6892) » Definitions » Stock Based Compensation

Taiwan Bio Therapeutics (ROCO:6892) Stock Based Compensation : NT$13.3 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Stock Based Compensation?

Taiwan Bio Therapeutics's Stock Based Compensation for the three months ended in Mar. 2025 was NT$2.3 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was NT$13.3 Mil.


Taiwan Bio Therapeutics Stock Based Compensation Historical Data

The historical data trend for Taiwan Bio Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Stock Based Compensation Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial - 7.33 12.41 9.00 15.05

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 3.28 3.53 4.14 2.35

Taiwan Bio Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$13.3 Mil.


Taiwan Bio Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.

Taiwan Bio Therapeutics Headlines

No Headlines